Diacerein in the treatment of osteoarthritis in patients with comorbidity
https://doi.org/10.14412/1996-7012-2018-4-54-58
Abstract
Osteoarthritis (OA) belongs to diseases with high comorbidity and is most frequently concurrent with hypertension and other cardiovascular diseases (coronary heart disease, atherosclerosis), obesity, and diabetes mellitus. The paper deals with the use of delayed-release symptomatic medications in the treatment of patients with OA and comorbidity. It reviews clinical trials of the efficacy and safety of diacerein in OA patients and its effect on comorbidity. The paper discusses the possibility of using diacerein as an alternative to traditional nonsteroidal anti-inflammatory drugs in patients with contraindications to the latter.
About the Authors
E. P. Sharapova
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
Russian Federation
Evgenia Pavlovna Sharapova.
34A, Kashirskoe Shosse, Moscow 115522.
L. I. Alekseeva
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Arden N, Nevit MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25.
2. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of health care. Ann Rheum Dis. 2001 Feb;60(2):91-7.
3. Galushko EA. Medical and social significance of rheumatic diseases. Autoref. diss. doct. med. sci. Moscow; 2011.
4. Sangha O. Epidemiology of rheumatic disease. Rheumatology (Oxford). 2000 Dec;39 Suppl 2:3-12.
5. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013 Feb;39(1):1-19. doi: 10.1016/j.rdc.2012.10.004. Epub 2012 Nov 10.
6. Nguyen US, Zhang Y, Zhu Y, et al. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med. 2011 Dec 6;155(11): 725-32. doi: 10.7326/0003-4819-155-11-201112060-00004.
7. Feinstein AR. Pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970 Dec;23(7):455-68.
8. Kraemer HC. Statistical issues in assessing comorbidity. Stat Med. 1995 Apr 30;14(8):721-33.
9. Van den Akker M, Buntinx F, Roos S, Knottnerus JA. Comorbidity or multimorbidity: what is in a name? A review of the literature. Eur J Gen Pract. 1996;2(2):65-70.
10. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the nonsurgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3): 363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
11. Van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alfa, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen-and zymosan - induced arthritis. Arthritis Rheum. 1995 Feb;38(2):164-72.
12. Pelletier JP, Mineau F, Ranger P, et al. The increased synthesis of inducible nitric oxide inhibites IL-1a synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteo Cart 1996; 4 (1):77-84.
13. Cruz TF, Tang J, Pronost S, Pujol JP. Molecular mechanisms implicated in the inhibition of collagenase expression by diacerhein. Rev Prat. 1996 Mar 15;46(6 Spec No): S15-S19.
14. Carney SL, Hicks CA, Tree B, Broadmore RJ. An in vivo investigation of the effect of anthraquinones on the turnover of aggrecans in spontaneous osteoarthritis in the guinea pig. Inflamm Res. 1995 Apr;44(4):182-6.
15. Pelletier JP, Mineau F, Fernandes JC, et al. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998 Dec;25(12):2417-24.
16. Mendes AF, Caramona MM, de Carvalho AP, et al. Diacerhein and Rhein prevent interleukin 1beta induced nuclear factor-kappa B activation inhibiting the degradation on inhibitor kappa B alpha. Pharmacol Toxicol. 2002 Jul;91(1):22-8.
17. Bendele AN, Bendele RA, Hulman JF, Swann BP. Benefical effects of treatment with diacerhein in guinea pigs with osteoarthritis. Rev Prat. 1996 Mar 15;46(6 Spec No): S35-S39.
18. Brandt KD, Smith G, Kang SY, et al. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage. 1997 Nov;5(6):438-49.
19. Moore AR, Greenslade KJ, Alam CA, Willoughby DA. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage. 1998 Jan; 6(1):19-23.
20. Smith GN Jr, Myers SL, Brandt KD, et al. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciatedeficiency model of osteoarthritis. Arthritis Rheum. 1999 Mar;42(3):545-54.
21. Nguyen M, Dougados M, Berdah L, et al. Diacerein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994 Apr;37(4): 529-36.
22. Marcolongo R, Fioravanti A, Adami S, et al. Efficacy and tolerability of diacerhein in the treatment of osteoarthritis. Curr Therap Res. 1988;43:878-87.
23. Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, doubleblind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007 Dec;56(12):4055-64.
24. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006 Sep 25;166(17): 1899-906.
25. Noskov SM, Krasivina IG, Shirokova KYu, et al. Diacerein in the treatment of patients with osteoarthritis and obesity. Theses of VII all- Russian conference «Rheumatology in real clinical practice». Moscow; 2012. P. 37.
26. Leushina EA, Simonova OV. Clinical efficacy of diacerein in osteoarthritis of the joints of the hands. Theses of VII all-Russian conference «Rheumatology in real clinical practice». Moscow; 2012. P. 109.
27. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1): CD005117.
28. Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-placebo-controlled trial. Arthritis Rheum. 2001 Nov; 44(11):2539-47.
29. Sharapova EP, Kashevarova NG, Zaitseva EM, et al. Evaluation of efficacy and safety of diacetin in patients with osteoarthritis of the hip joints. Meditsinskii sovet. 2017;(1S): 84-90. (In Russ.).
30. Zhou YX, Xia W, Yue W, et al. Rhein: A review of pharmacological activities. Evid Based Complement Alternat Med. 2015;2015:578107. doi: 10.1155/2015/578107. Epub 2015 Jun 22.
31. Naumov AV, Khovasova NO. Recommended osteoarthritis therapy: new solutions to old problems. Russkii Meditsinskii Zhurnal. 2016; 24(3):197-202 (In Russ.).
32. Jatwa R, Kar A. Anti-inflammatory and anti-peroxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation. Fundam Clin Pharmacol. 2009 Aug;23(4):465-71. doi: 10.1111/j.1472-8206.2009.00685.x. Epub 2009 Jun 3.
33. Alekseeva LI, Kashevarova NG, Taskina EA, et al. Efficacy and safety of diacerein in patients with knee osteoarthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(3): 50-7 (In Russ.). doi: 10/14412/1996-7012-2017-3-50-57
34. Alekseeva LI, Taskina EA, Kashevarova NG, et al. Knee osteoarthritis and metabolic syndrome: new approaches to therapy. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(2):157–63. (In Russ.). doi: 10.14412/1995-4484-2018-157-163
35. Naumov AV, Alekseeva LI. Vedenie bol'nykh s osteoartritom i komorbidnost'yu v obshchei vrachebnoi praktike. Klinicheskie rekomendatsii [Management of patients with osteoarthritis and comorbidity in General medical practice. Clinical guidelines]. Moscow: Rossiiskoe nauchnoe meditsinskoe obshchestvo terapevtov; 2016. 40 p.
Review
For citations:
Sharapova EP, Alekseeva LI, Lila AM. Diacerein in the treatment of osteoarthritis in patients with comorbidity. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(4):54-58. (In Russ.) https://doi.org/10.14412/1996-7012-2018-4-54-58
Views:
1140
Email this article 